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ABSTRACT
In previous studies, we have reported that phospholipase C (PLC)-β1 plays a 
crucial role in myogenic differentiation and we determined the importance of its 
catalytic activity for the initiation of this process. Here we define the effectors that take 
part to its signaling pathway. We show that the Inositol Polyphosphate Multikinase 
(IPMK) is able to promote myogenic differentiation since its overexpression determines 
the up-regulation of several myogenic markers. Moreover, we demonstrate that IPMK 
activates the same cyclin D3 promoter region targeted by PLC-β1 and that IPMK-
induced promoter activation relies upon c-jun binding to the promoter, as we have 
shown previously for PLC-β1. Furthermore, our data shows that IPMK overexpression 
causes an increase in β-catenin translocation and accumulation to the nuclei of 
differentiating myoblasts resulting in higher MyoD activation. Finally, we describe that  
PLC-β1 overexpression determines too an increase in β-catenin translocation and 
that PLC-β1, IPMK and β-catenin are mediators of the same signaling pathway since 
their overexpression results in cyclin D3 and myosin heavy chain (MYH) induction.
INTRODUCTION
Myogenic differentiation is a well-defined and highly 
ordered process that involves several distinct and complex 
events: myoblasts proliferation, cell-cycle withdrawal, 
cell migration, alignment and fusion into multinucleated 
myotubes [1]. The regulation of these processes requires 
the activation of several transcription factors belonging 
to two main families: the MRFs (Myogenic Regulatory 
Factors) and MEF2 (Myocyte Enhancer Factor-2) family 
[2]. In particular, the MRFs comprise Myf5, MyoD, 
myogenin and MRF4; they can regulate each other’s 
expression and interact with the MEF2 transcription factors 
to induce the transcription of muscle-specific genes [3]. 
The expression of MRFs can drive both myogenic and non-
myogenic cell lines into myogenic differentiation [4, 5]. 
Myf5 and MyoD are expressed early in cell committed to 
differentiation while myogenin and MRF4 are expressed 
when cells enter terminal differentiation [6–8].
The fate of the myoblast that is whether it should 
continue to proliferate or start differentiating, is the result 
of the balance between positive and negative cell-cycle 
regulators. Eventually, the activation of differentiation 
process leads to the expression of late differentiation 
markers such as troponin, tropomyosin and myosin heavy 
and light chains that are among the downstream targets of 
MRFs and MEF2 family.
In previous studies, we investigated the role 
of phospholipase C(PLC)-β1-dependent signaling in 
myogenic differentiation using C2C12 murine myoblasts. 
C2C12 cells can differentiate into myotubes, under low 
serum conditions and represent a well-established and 
reproducible model of myogenesis used for studying many 
muscle-specific genes and proteins [9].
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PLC-β1 belongs to the family of PLCs that 
comprises 13 enzymes, divided into six classes based on 
their different domain composition. PLC-β1 catalyzes 
the hydrolysis of the signaling lipid phosphatidylinositol 
4,5-bisphosphate (PI(4,5P)
2
) generating two important 
second messengers: inositol 1,4,5,-trisphosphate (IP
3
) 
and diacylglycerol (DAG), which in turn regulate several 
cellular processes [10]. PLC-β1 presents two splicing 
variants: β1a and β1b that differ in their C-terminal region. 
The two variants show different cellular distribution: 
while PLC-β1a is located specially in the cytosol, PLC-
β1b is mainly distributed to the nucleus [11].
We have previously demonstrated that during 
C2C12 myoblast differentiation PLC-β1 expression is 
highly induced and that its catalytic activity is essential 
for the onset of the differentiation program. Moreover, 
the activation of PLC-β1-dependent pathway determines 
the up-regulation of cyclin D3 promoter activity leading 
to an increase in cyclin D3 expression during myogenic 
differentiation.  In a following study, we identified the 
cyclin D3 promoter region specifically targeted by PLC-β1 
signaling activity, and we described the transcription factor 
c-jun as the mediator for promoter activation [12–15].
In this study, we wanted to understand better 
the pathway induced by PLC-β1 during myogenic 
differentiation. We hypothesized that the second messenger 
IP
3
 generated by PLC-β1 activity could be the substrate of 
Inositol Polyphosphate Multikinase (IPMK) leading to the 
production of higher phosphorylated inositol species. 
IPMK is a multifunctional enzyme that shows 
both IP3- and IP4-kinase, and PI3-kinase activity. It is 
essential for the production of IP
4
 (both Ins(1,3,4,5)P
4
 and 
Ins(1,4,5,6)P
4
) and IP
5
 [16,17]. IPMK is crucial for the 
production of higher phosphorylated inositol species, since 
it is the only enzyme capable to produce Ins(1,4,5,6)P
4
 
and IP
5
. Therefore IPMK depletion results in the nearly 
complete elimination of intracellular IP
6
 and IP
7
 [17]. 
IPMK can also act as a PI3-kinase phosphorylating PIP
2
 
at the 3, position in order to produce PIP
3 
[18]. Moreover, 
it shows catalytic-independent activities as it can bind and 
stabilize the mTOR (mammalian Target of Rapamicin) 
complex [19] as well as function as a transcriptional co-
activator for serum response factor [19], CREB (cAMP 
response element)-binding protein [20] and p53 [21,22].
Since it was described in a different model that 
IP
5
 produced by IPMK could induce the Wnt/β-catenin 
pathway, we hypothesized that β-catenin could be a 
mediator of PLC-β1 pathway in myogenic differentiation 
[23]. The activation of Wnt/β-catenin pathway leads to 
the accumulation of β-catenin and its translocation to the 
nucleus where it induces downstream gene expression. 
When the pathway is not activated, β-catenin is bound 
to axin, adenomatous polyposis coli (APC), glycogen 
synthase kinase (GSK) 3β and casein kinase 1 that induce 
β-catenin proteasomal degradation [24]. Βeta-catenin 
target genes are involved in several cellular processes, such 
as proliferation, differentiation, survival and angiogenesis, 
as well as cancer initiation and progression [25].
Our results show that IPMK promotes myogenic 
differentiation of C2C12 cells. Moreover, IPMK is 
involved in PLC-β1-dependent signaling since it activates 
the same cyclin D3 promoter region targeted by PLC-β1, 
and we show that the promoter activation depends 
upon c-jun binding. Furthermore, we investigated the 
involvement of β-catenin in myogenic differentiation 
and we present its nuclear translocation in response to 
IPMK overexpression. Taken together our data is useful 
to define better the PLC-β1-dependent signaling pathway 
in myogenic differentiation.
RESULTS
IPMK overexpression promotes myogenic 
differentiation
Since we demonstrated that PLC-β1-depedent 
signaling is involved in myogenic differentiation, 
we wanted to understand further how this process 
is accomplished [13]. PLC-β1 activation yields to 
diacylglycerol (DAG) and inositol (1,4,5)- trisphosphate 
(IP
3
) production, therefore we hypothesized that IP
3
 could 
be the substrate of Inositol Polyphosphate Multikinase 
(IPMK) generating higher phosphorylated inositol species. 
First, we evaluated IPMK expression during the 
differentiation of C2C12 cells. Since we have not found 
a good commercial antibody for IPMK, we tested its 
expression in real-time PCR. Figure 1A shows IMPK 
expression in growing (GM) and differentiating cells, 
respectively 24 h, 48 h and 72 h after medium switch 
(DM). It is clear that IPMK expression did not vary during 
myogenic differentiation.
Then, we overexpressed IPMK in C2C12 cells, 
we induced the differentiation and we tested at different 
time points the expression of genes involved in the 
differentiation process, namely: myogenin, cyclin D3, 
and cyclin D1. Samples were collected following the 
incubation in growth medium (GM) and 24 h, and 
48 h after differentiation induction (DM). As shown in 
Figure 1B IPMK overexpression determined an increase 
in the expression of myogenin and cyclin D3 even before 
the switch from growth medium (GM) to differentiation 
medium (DM). It caused also a marked decrease in cyclin 
D1 expression (Figure 1C), strongly supporting a role for 
IPMK in myogenic differentiation.
Moreover, we tested if the changes that we observed at 
the transcriptional level corresponded to changes in protein 
expression. Therefore, we evaluated myogenin, cyclin D3 
and, myosin heavy chain (MYH) expression in whole cell 
lysates of C2C12 cells overexpressing DDK-tagged IPMK, 
kept in GM and 24, and 48 hours after DM administration. 
As displayed in Figure 1D, cells overexpressing IPMK 
showed higher levels of differentiation markers.
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The above data strongly suggest that IPMK plays 
a role in promoting the differentiation of C2C12 skeletal 
muscle cells.
Effects of IPMK on cyclin D3 promoter 
activation
In a previous study, we have demonstrated that PLC-
β1-dependent signaling determined cyclin D3 promoter 
activation during muscle differentiation and it targeted 
a specific promoter region, i.e. the region spanning 
from -446 to -190 bp, containing the binding site for the 
transcription factor c-jun [12]. 
In order to further assess IPMK involvement in 
myogenic differentiation, we investigated the ability of 
IPMK to activate the same cyclin D3 promoter region 
targeted by PLC-β1. Briefly, C2C12 cells were transfected 
with pD3-957 reporter vector, coding for the human 
growth hormone (hGH) under control of the −957 to +1 
cyclin D3 promoter fragment and with an empty vector 
(mock) or a vector coding for IPMK. HGH production 
was evaluated 24 h after differentiation induction. Notably, 
Figure 2 shows that transient overexpression of IPMK 
caused an increase in hGH production due to higher cyclin 
D3 promoter activity and the activity was even higher 
when GM was replaced with DM.
Moreover, we performed the reporter gene assay 
using a pD3-957 vector in which c-jun binding site has 
been mutated (pD3-957mut). As described in [13], PLC-
β1-dependent cyclin D3 promoter activation requires 
c-jun binding. In order to understand if IPMK takes part 
to the same pathway induced by PLC-β1 during muscle 
differentiation, we tested IPMK ability to activate the 
mutated cyclin D3 promoter. We co-transfected C2C12 
cells with an empty vector (mock) or with IPMK coding 
vector and with wild type (pD3-957) or mutated pD3-957 
(pD3-957mut) vector. Then we compared hGH production 
24 h after the differentiation induction. Figure 2 shows 
that IPMK overexpression could no longer activate the 
mutated promoter even after DM administration, while 
Figure 1: IPMK overexpression promotes myogenic differentiation. (A): IPMK expression was evaluated by real-time PCR in 
C2C12 cells in growing medium (GM) and after 24, 48 and 72 h culture in differentiation medium (respectively 24 DM, 48 DM, 72 DM). 
(B), (C) and (D): IPMK was overexpressed in C2C12 cells and the expression of myogenic markers was evaluated in growing cells (GM), 
24 h, and 48 h after switching to differentiation medium (24 DM and 48 DM). The expression of IPMK, myogenin, cyclin D3 (panel B) 
and cyclin D1 (panel C) was evaluated by real –time PCR. Data are from three independent experiments, *p < 0.05 vs corresponding ctrl 
sample. The expression of myosin heavy chain (MYH), cyclin D3, myogenin, and DDK-tagged IPMK was evaluated by Western blot using 
tubulin as loading control (panel D). Data are from three independent sets of experiments.
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cells transfected with native pD3-957 vector showed the 
expected hGH production. Therefore, these data underline 
that IPMK takes part to PLC-β1-dependent pathway, as it 
requires the same transcription factor, i.e. c-jun, in order 
to activate cyclin D3 promoter.
IPMK promotes nuclear β-catenin translocation 
during myogenic differentiation
It has been described that canonical Wnt signaling 
is involved in myoblast differentiation. Wnt signaling 
induces β-catenin shuttling from the cytoplasm to the 
nucleus, but it is still unknown the mechanisms that lead 
to β-catenin activation [26]. It was also demonstrated 
that inositol pentakisphosphate (IP
5
) can stimulate casein 
kinase2 (CK2) activity promoting nuclear β-catenin 
accumulation [27]. Therefore, we explored whether 
IPMK could be in involved in regulating β-catenin 
accumulation in the nuclear compartment during 
myogenic differentiation. We overexpressed DDK-tagged 
IPMK in C2C12 cells and we probed the nuclear lysates 
of growing and differentiating cells, 48 h after switching 
to DM. Firstly, these results indicated that during 
myogenic differentiation nuclear β-catenin accumulation 
is increased. Moreover, nuclear extracts of samples 
that overexpressed IPMK presented a marked raise in 
β-catenin as well as in MyoD, a well-known myogenic 
marker, accumulation compared to controls (Figure 3A). 
IPMK overexpression was checked in whole cell lysates 
in growing (GM) and differentiating (48 DM) samples 
(Figure 3B).
Therefore, IPMK overexpression induces 
β-catenin accumulation to the nuclear compartment 
and it promotes myogenic differentiation, as shown 
by MyoD increase, a fundamental event in the 
differentiation process.
Defining PLC-β1 signaling in myogenic 
differentiation: IPMK, β-catenin and cyclin D3 
Since we demonstrated that β-catenin is a 
downstream effector of IPMK activity, we wanted to 
investigate the effect of PLC-β1 overexpression on 
β-catenin nuclear accumulation.
We transfected C2C12 cells with a vector coding 
for PLC-β1 and we induced the differentiation, then we 
tested nuclear extracts for β-catenin expression. As shown 
in Figure 4A PLC-β1 overexpression determined higher 
β-catenin nuclear accumulation as compared to mock-
transfected sample. Hence, as we showed for IPMK also 
PLC-β1 overexpression induced β-catenin accumulation to 
the nuclear compartment. 
Moreover, we investigated the effect of β-catenin 
overexpression on cyclin D3 in order to define the 
factors involved in PLC-β1 pathway during myogenesis. 
We overexpressed β-catenin in C2C12 myoblasts and 
we tested the nuclear extracts for cyclin D3 expression 
48 h after inducing the differentiation. Figure 4B shows 
that β-catenin overexpression determines cyclin D3 
accumulation both in growing and in differentiating cells. 
Furthermore, we investigated the effect of the 
overexpression of PLC-β1, β-catenin and IPMK on 
myogenic differentiation. Cells were transfected with the 
vectors coding for the proteins cited above and whole 
cell lysates were tested for myosin heavy chain (MYH) 
expression 48 h after the induction of differentiation. 
Figure 4C displays that the overexpression of all these 
proteins determined an increase in myosin heavy chain 
expression as compared to the mock-transfected sample, 
confirming that they are all involved in promoting 
myogenic differentiation.
Finally, in order to determine whether the effect 
of IPMK overexpression was due to its catalytic activity, 
Figure 2: Effects of IPMK on cyclin D3 promoter activation. C2C12 cells were co-transfected with an empty vector (mock) 
or a vector coding for IPMK (IPMK) and either with a reporter vector coding for human growth hormone (hGH) under control of a 
fragment of cyclin D3 promoter (pD3-957) or with the same vector bearing a mutation in c-jun consensus sequence in the promoter region 
(pD3-957 mut). hGH production was evaluated in growing cells (GM) and 24 h after the induction of differentiation (DM). Data are from 
three independent experiments, *p < 0.05 vs corresponding mock sample and °p < 0.05 vs corresponding pD3-957 sample.
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Figure 4: Effects of PLC-β1, β-catenin and IPMK overexpression on myogenic differentiation. C2C12 cells were 
transfected with and empty vector (Mock) or a vector coding for PLC-β1 (ov-β1, panel A and C) or for β-catenin (ovβcat, panel B and C) or 
DDK-tagged IPMK (ovIMPK, panel C). After 48 h of differentiation, growing cells (GM) and differentiating cells (48 DM) were harvested. 
Nuclear extracts were tested for β-catenin (panel A) and cyclin D3 (panel B) expression and histone was used as loading control. Whole 
cell lysate (panel C) were tested for myosin heavy chain expression (MYH) and tubulin was used as loading control. Data are from three 
independent experiments.
Figure 3: IPMK promotes β-catenin nuclear accumulation. C2C12 cell were transfected with an empty vector (Ctrl) or DDK-
tagged IPMK vector (ovIpmk). Cells were grown in growing medium (GM) or in differentiation medium (48 DM) for 48 h and (A) nuclear 
extracts were tested for β-catenin and Myo-D expression. Histone was used as loading control. (B) IPMK expression was tested on whole 
cell lysate from the same samples. Data are from three independent experiments.
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we overexpressed the following IPMK mutants: a kinase 
dead mutant (IPMK SA), an inositol-binding site mutant 
(IPMK KA) and a double mutant (IPMK KA/SA). 24 
hours after transfection growth medium was replaced with 
differentiation medium and we evaluated the expression of 
myogenic markers 24 h and 72 h after switching the medium.
24 h after the induction of differentiation, we 
compared by real-time PCR the expression of myogenin 
and cyclin D3 between cells transfected with an empty 
vector and with vectors coding for wild type IPMK and for 
IPMK mutants. Figure 5A shows that the overexpression 
of IPMK mutants does not determine a variation in 
myogenic markers expression compared to the mock- 
transfected control sample. 72 hours after switching to 
differentiation medium, we checked myosin heavy chain, 
β-catenin and cyclin D3 expression on whole cell lysates 
of transfected cells. Figure 5B shows that while the 
overexpression of wild type IPMK (ovIPMK) determines 
an increase in markers expression, the expression of the 
three mutants (ovSA, ovKA, ovKA/SA) does not induce 
myogenic markers.
DISCUSSION
Skeletal muscle differentiation is an extremely 
complicated and highly regulated process that involves 
cellular interactions and extracellular signaling molecules, 
including Wnts, Sonic hedgehog (Shh), and bone 
morphogenetic proteins (BMPs), which are secreted from 
the surrounding environment. These signaling proteins 
induce transcription factor networks that cause several cell 
events resulting in cell differentiation [28, 29].
In previous studies, we have described the relevance 
of PLC-β1-dependent signaling pathway in myogenic 
differentiation since not only PLC-β1 expression increases 
during differentiation [14] but its overexpression is able 
to induce the differentiation process. Moreover, PLC-β1 
silencing results in the inhibition of the onset of the 
differentiation program [12]. Muscle cells differentiation 
is characterized by the induction of myogenic markers 
and by the increase of cyclin D3 expression due to 
transcriptional activation of its promoter. We demonstrated 
that PLC-β1-dependent signaling pathway can activate 
cyclin D3 promoter during the differentiation of 
myoblasts to myotubes, indicating that PLC-β1 is an 
important regulator of cyclin D3 gene expression [12, 
14, 30]. In this study, we aimed to elucidate further 
PLC-β1 signaling pathway and its downstream targets in 
myogenic differentiation. The data we presented indicate 
that IPMK and β-catenin are both involved in determining 
the induction of myogenin, cyclin D3 and myosin heavy 
chain (MYH) during the differentiation process. 
Despite the importance of higher phosphorylated 
inositol species for several cellular functions, IPMK 
physiologic and pathologic regulations are still largely 
unexplored. Recently, a group has reported that IPMK 
expression is profoundly reduced in Huntington’s 
disease. They showed that IPMK depletion causes 
neural dysfunction, and restoration of IPMK delays the 
progression of behavioral abnormalities and rescues striatal 
pathology [31]. Until now, studies about the role of IPMK 
in skeletal muscle differentiation or muscular diseases were 
lacking. This prompted us to explore IPMK involvement 
in myogenic differentiation. Since we showed that PLC-β1 
catalytic activity is required for myogenic differentiation 
[13], we hypothesized that the second messenger IP
3
, 
produced by PLC-β1, could be the substrate of IPMK 
to generate higher phosphorylated inositol species that 
could be required for the differentiation process. Firstly, 
we investigated whether IPMK expression showed any 
changes during C2C12 differentiation. However, IPMK 
expression did not show any relevant variation. Since 
Figure 5: Effects of IPMK mutants’ overexpression on myogenic differentiation. C2C12 cell were transfected with an empty 
vector (Mock) or vectors coding for wild type IPMK (ovIpmk), IPMK kinase-dead mutant (ovSA), IPMK mutated in the inositol-binding 
site (ovKA) or IPMK double mutant (ovKA/SA). 24 h after transfection growth medium was switched to differentiation medium (DM). (A) 
24 h after changing the medium to DM, IPMK, myogenin and cyclin D3 expression was evaluated by real –time PCR. Data are from three 
independent experiments, *p < 0.05 vs mock sample. (B) 72 h after changing the medium to DM, whole cell lysates were tested for myosin 
heavy chain, β-catenin and cyclin D3 expression. Tubulin was used as loading control. 
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IPMK silencing resulted in cell death, probably due to 
inositol pentakisphosphate (IP
5
) depletion, we decided to 
evaluate the effects of its overexpression on several genes 
involved in myogenic differentiation. Our data showed 
that IPMK overexpression promoted the differentiation of 
C2C12 skeletal muscle cells as it elicited the induction of 
myogenin, cyclin D3 and myosin heavy chain. 
In previous studies, we have shown that PLC-β1 is 
able to induce the differentiation of C2C12 myoblasts by 
targeting a specific region of the cyclin D3 promoter and 
that PLC-β1 is a key regulator of cyclin D3 transcription 
[12]. Our data showed that the increase in cyclin D3 
expression is actually due to the activation of the 
transcription factor c-jun, a member of AP-1 transcription 
complex, through PLC-β1-dependent signaling pathway 
[13]. In this work, we show that IPMK is also involved 
in the regulation of cyclin D3 expression. In order to 
identify the transcription factor activated by IPMK, we 
mutated c-jun binding site in a specific cyclin D3 promoter 
region that presents the binding sites for several other 
transcription factors. The failure of IPMK overexpression 
to activate the mutated promoter confirms the crucial 
role of c-jun in IPMK-dependent promoter activation. 
Therefore, IPMK overexpression determines an increase 
in cyclin D3 promoter activation by targeting the same 
transcription factor activated by PLC-β1 overexpression, 
i.e. c-jun, suggesting that the two enzymes take part to the 
same signaling pathway. 
It has been demonstrated that inositol 
1,3,4,5-tetrakisphosphate (IP
4
), inositol pentakisphosphate 
(IP
5
) and inositol hexakisphosphate (IP
6
) can stimulate 
casein kinase 2 (CK2) activity which in turn suppresses 
β-catenin degradation and binding to adenomatous 
polyposis coli (APC) promoting β-catenin accumulation 
to the nuclear compartment [23, 32–34]. Once in the 
nucleus β-catenin recruits cofactors of the TCF/LEF 
family and induces the transcription of its target genes 
[35]. Consequently, inositol polyphosphates can positively 
regulate the Wnt/ β-catenin pathway. Wnt signaling 
pathway plays an important role in muscle development 
and regeneration as it is involved in the switching from 
cell proliferation to myogenic differentiation in mouse 
myoblasts [26, 36].Therefore, we decided to analyze the 
expression of the main component of the canonical Wnt 
signaling pathway, i.e. β-catenin, in response to IPMK 
overexpression. Beta-catenin plays an important role 
in a wide variety of cellular processes, including stem 
cell proliferation and tissue regeneration, as well as in 
cancer progression [37]. We demonstrated that IPMK 
overexpression is able to induce β-catenin accumulation 
to the nuclear compartment, which is a fundamental event 
in myogenic differentiation progression. Moreover, it has 
been proven that c-jun is one of β-catenin target genes 
since its promoter is activated by β-catenin overexpression 
[38], supporting the hypothesis that β-catenin might act 
downstream IPMK in order to activate cyclin D3 promoter.
Furthermore, in order to determine whether 
PLC-β1, IPMK, β- catenin and cyclin D3 belong to the 
same signaling pathway activated during myogenic 
differentiation, we performed a series of overexpression 
experiments. We showed that PLC-β1 overexpression 
induces β-catenin accumulation in the nucleus and in turn, 
β-catenin overexpression determines an increase in cyclin 
D3 but it does not affect PLC-β1 expression. Moreover, 
both PLC-β1 and IPMK overexpression causes β-catenin 
accumulation, as shown in Figure 4C. Additionally, 
the expression levels of myosin heavy chain increased 
considerably following to the overexpression of PLC-β1, 
β-catenin or IPMK.
Finally, Xu et al. demonstrated that IPMK is able 
to induce the transcription of several genes independently 
of its inositol phosphate and lipid kinase activities. In 
particular, they showed that IPMK can induce several 
immediate early genes in neural activation [20], and can 
stimulate p53-dependent transcription in stress responses 
by binding to p53 and enhancing its acetylation by p300 
acetyltransferase [21]. Therefore, we tested whether IPMK 
catalytic activity was required for myogenic markers 
induction. The overexpression of three IPMK mutants, 
respectively a kinase dead-mutant, an inositol binding site-
mutant and a double mutant, failed to induce myogenic 
markers expression demonstrating that IPMK lipid kinase 
activity is required for myoblasts differentiation.
Taken together our data identify new mediators 
of PLC-β1- dependent signaling pathway in myogenic 
differentiation. The model we propose suggests that 
following to PLC-β1 accumulation PIP
2
 is hydrolyzed 
producing IP
3
, which is sequentially phosphorylated by 
IPMK leading to the formation of higher phosphorylated 
inositol species, like IP
4
, IP
5
 and IP
6
. IP
5
 accumulation 
determines β-catenin translocation to the nucleus where it 
activates c-jun, which in turn activates cyclin D3 promoter. 
Although further studies are required to elucidate all the 
molecular mechanisms underlying PLC-β1 signaling in 
myogenic differentiation, it is striking to state that these 
results identify a series of events related to a common 
pathway that lead to the same target activation, that is 
cyclin D3 promoter.
MATERIALS AND METHODS
Cell culture, differentiation and transfection
Murine myoblast C2C12 cells (American Type 
Culture Collection, Manassas, VA) were cultured at sub-
confluent density in growth medium (GM) consisting of 
high glucose DMEM (Sigma–Aldrich, St. Louis, MO) 
supplemented with 10% fetal bovine serum (Sigma-
Aldrich) and antibiotics (100 U/ml penicillin, 100 mg/ml 
streptomycin, Sigma–Aldrich). To induce differentiation, 
confluent C2C12 cells were cultured in differentiation 
medium (DM) consisting of DMEM supplemented with 
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2% horse serum (Sigma-Aldrich) and antibiotics, for 24, 
48 or 72 h as reported in the Figures.
For protein expression analysis and reporter gene 
assays, C2C12 cells were transfected using Lipofectamine 
2000 from Life Technologies, following manufacturer’s 
instructions. One day before transfection 1,5 × 105 
cells per well were seeded in 6-well plates or 1,5 × 106 
cells in T25 flasks, 24 h post-transfection the medium 
was replaced either with growing medium (GM) or 
differentiation medium (DM), and the cells were kept in 
this medium for the time described in the Figures.
Expression vectors
The vector coding for Myc-DDK- tagged mouse 
IPMK (TrueORF clone, MR206205) was purchased from 
OriGene (Rockville, MD).
The pD3-957 plasmid containing the human growth 
hormone (hGH) reporter gene under the control of 
cyclin D3 promoter region spanning from−957 bp to the 
transcription start site was generated as described in [39]. 
The c-jun mutated vector (pD3-957mut) was obtained by 
sited-directed mutagenesis in pD3-957 promoter fragment 
as reported in [13].
For PLC-β1 expression experiments, PLC-β1a 
was cloned in pcDNA/2.1 vector (LifeTechnologies, 
Carlsbad, CA). 
pcDNA3.1/nV5-DEST-β-catenin expression vector 
was purchased from Addgene (Cambridge, MA), kindly 
provided by Valeri Vasioukhin, Fred Hutchinson Cancer 
Research Center, Seattle.
pCMV vectors coding for human wild type IPMK, 
IPMK kinase-dead mutant (IPMK SA), IPMK mutated in 
the inositol-binding site (IPMK KA) and IPMK double 
mutant (IPMK KA/SA) were designed as described in [40].
Reporter gene assay
For each sample 1,5 × 105 C2C12 cells were 
co-transfected using Lipofectamine 2000, as described 
above, with 1 μg of expression vector and 1 μg of reporter 
vector. We used empty pcDNA 2.1 (Mock) and TrueORF- 
Ipmk as expression vectors. pD3-957 or its c-jun-mutated 
construct (pD3-957mut) were used as reporter vectors. 
24 h after transfection medium was replaced either with 
growth medium (GM) or differentiation medium (DM). 
The promoter activity was evaluated 24 h after the medium 
switch by measuring hGH concentration in cell medium 
by using hGH ELISA kit (Roche, Indianapolis, IN).
RNA extraction, retrotranscription and real-time 
PCR
Total RNA was extracted form growing or 
differentiating C2C12 cells at different time points, using 
RNeasy mini kit (Qiagen, Hilden, Germany). RNA was 
quantified using a Nanodrop and cDNAwas synthesized 
starting from 2 μg of total RNA using 200 U of M-MLV 
retro-transcriptase (Promega, Madison,WI), 0.5 μg of 
oligo-dT primers, 25 U ribonuclease inhibitor, 10 mM of 
each dNTP. The reactions were incubated for 1 h at 42°C. 
Gene expression was determined by using a TaqMan 
based real-time PCR method. We used the following 
validated assays: Ipmk Mm01148668_m1, myogenin 
Mm00446194_m1, cyclin D3 Mm01273583_m1, cyclin 
D1 Mm00432359_m1 (Applied Biosystems, Foster City, 
CA). GAPDH was used as the reference housekeeping 
gene (assay no. Mm99999915_g1, Applied Biosystems). 
Quantitative RT-PCR reactions were performed using 
TaqMan PCR universal master mix using the ABI PRISM 
7300 real-time PCR machine (Applied Biosystems). 
Samples were analyzed in triplicate. Gene expression 
was analyzed using relative quantification and the ΔΔCt 
method. The results of different sets of experiments were 
statistically analyzed by GraphPad Prism version 3.02.
Protein extraction and western blot analysis
Whole cell lysate were obtained by lysing the cells 
in M-PER extraction reagent (Thermo Fisher Scientific) 
supplemented with Halt protease inhibitor cocktail 
(Thermo Scientific).
For nuclear purification 2,5 × 106 cells were 
suspended in 250 µl of swelling buffer [10mM Tris-HCl 
(pH 7.4), 1% Nonidet P-40, 10mM β-mercaptoethanol, 
0.5mM phenylmethylsulfonyl fluoride] supplemented 
with Halt protease inhibitor cocktail and kept on ice for 
5 minutes. Then 250 µl of ice-cold water were added. 
After 3 min, cells were sheared by eight passages through 
a 23-gauge hypodermic needle. Nuclei were recovered by 
centrifugation at 400 g at 4°C for 6 min and washed once 
in 400 µl of washing buffer [10mM Tris-HCl (pH 7.4) 
and 2 mM MgCl2, plus protease inhibitors as describe 
above]. The purity of the isolated nuclei was determined 
by western blotting using an anti-β-tubulin antibody. 
Protein concentrations were determined by the method of 
Bradford.
For western blot analysis, 50 µg of proteins from 
whole-cell extracts or 20 µg from nuclear extracts were 
separated on 4–12% polyacrylamide-0.1% SDS gels (Life 
Technologies). Proteins were transferred to nitrocellulose 
membranes and proved with specific antibodies, detected 
with horseradish peroxidase-conjugated secondary 
antibody. The immunoreactive bands were visualized 
using an ECL enhanced chemiluminescence system 
(Thermo Scientific) and visualized in a Kodak digital 
image station 2000R. The expression of specific proteins 
was analyzed by using the following antibodies: anti-
MYH monoclonal antibody (sc-376157), anti-myogenin 
monoclonal antibody (sc-12732), anti-MyoD monoclonal 
antibody (sc-377460) and anti-PLC-β1 (sc-9050) 
antibody were purchased from Santa Cruz Biotechnology 
Oncotarget84126www.impactjournals.com/oncotarget
(Santa Cruz, CA); monoclonal Cyclin D3 (#2936), anti-β-
catenin antibody (#9587) and anti-Histone H2A.X antibody 
(#2595) from Cell Signaling Technology, Inc., (Danvers, 
MA). Anti-Flag M5 monoclonal antibody (F1804) used 
for detecting DKK-tag and anti-βtubulin antibody (T7816) 
were purchased from Sigma-Aldrich (MO, USA). 
Statistical analysis and image analysis
Real-time PCR results of myogenic markers 
expression and ELISA results of cyclin D3 promoter 
activation are reported as the mean ± SD of three 
independent sets of experiments. Data were analyzed 
using two-way ANOVA with Tukey’s tests for multiple 
comparisons. P values < 0.05 were considered statistically 
significant. All analyses were performed with GraphPad 
Prism version 3.02 for Windows. 
Images were quantified with ImageJ software. Data 
are from at least three independent experiments.
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